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Low levels of testosterone are manifested by erectile dysfunction, reduced sexual desire, and loss of morning erections with
increasing numbers of men are being diagnosed and require treatment. The prevalence rates of testosterone deficiency vary
according to different studies but may be as high as 40% in populations of patients with type 2 diabetes.There is increasing evidence
that testosterone deficiency is associated with increased cardiovascular and all-cause mortality. Screening for low testosterone is
recommended in a number of high risk groups including those with type 2 diabetes and metabolic syndrome. There are recent
data to suggest that testosterone replacement therapy may reduce cardiovascular mortality as well as improving multiple surrogate
markers for cardiovascular events. Specific clinical trials of testosterone replacement therapy are needed in selected populations
but in the meantime we must treat patients based on the best current evidence.
1. Introduction
The current ISSAM (International Society for Study of the
Aging Male), EAU (European Association of Urology), and
BSSM (British Society for Sexual Medicine Association)
definition of Late Onset Hypogonadism [1, 2] is
“A biochemical syndrome associated with advanc-
ing age and characterised by a deficiency in
serumandrogen levels with orwithout a decreased
genomic sensitivity to androgens. It may result in
significant alterations in the quality of life and
adversely affect the function of multiple organ
systems”.
This state of hypogonadism causes a global decrease in
energy and a decrease in the feeling of well-being. It also
causes a change in sexual function and has other endocrine
and metabolic repercussions. These can affect bones, mus-
cles, and lipids, as well as cognitive function Testosterone
Deficiency Syndrome (TDS) or Late Onset Hypogonadism
which is defined on the basis of clinical symptoms associated
with abnormal testosterone levels. The EuropeanMale Aging
Study [3] (EMAS) studied 3369 men aged 40−79 at 8
European centres and concluded that the 3 following cardinal
symptoms were most likely to be related to low levels of
testosterone.
Erectile Dysfunction, Reduced Sexual Desire, and Loss of
Morning Erections. Other symptoms such as hot flushes,
sweats and tiredness, loss of vitality, reduced shaving fre-
quency, gynaecomastia, depressed mood, poor concentra-
tion, and sleep disturbance were regarded as less specific.
Recent guidelines suggest that a level of total testosterone
of <8 nmol/L or free testosterone of less than 180 pmol/L
requires testosterone replacement therapy and total testos-
terone of>12 nmol/L or free testosterone of>225 pmol/L does
not. Between these levels a trial of therapy for a minimum of
6 months should be considered based on symptoms [1, 2]
2. Biochemical Assessment of Hypogonadism
Total testosterone should be measured between the hours of
7 and 11 am on 2 occasions at least 1 month apart and ideally
be assessed by mass spectrometry (ID-GCMS). Equilibrium
dialysis is currently the gold standard for free testosterone as
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immunoassays based on analogue displacement are currently
inaccurate [1, 2, 4].
TheEndocrine society [4] recommends thatmenwith the
following conditions should be screened for low testosterone
routinely:
(i) type 2 diabetes,
(ii) metabolic syndrome,
(iii) moderate to severe chronic lung disease,
(iv) osteoporosis,
(v) HIV,
(vi) history of infertility,
(vii) treatment with steroids, opiates (even medically pre-
scribed), and anticonvulsants,
(viii) alcohol abuse.
3. Low Testosterone and Increased Mortality
There is increasing evidence frommultiple long-term studies
that TDS is associated with increased cardiovascular and all-
causemortality [5–13]. Two recentmeta-analyses have looked
at a large number of long-term studies linking low testos-
terone to increased cardiovascular and all-cause mortality
[14, 15]. Araujo et al. [14] concluded that the evidence for a
link between low testosterone and increased mortality was
strong but concluded that most studies involved issues in
cohort selection and choice. They concluded that a decrease
of 2.1 standard deviations in total testosterone was associated
with a 25% increase in mortality. Haring [15] et al. looked at
the data in terms of several models and found that even after
strict adjustment for comorbidities there was a consistent link
between mortality risk and testosterone level throughout the
studies but that this did not prove causation (Table 1).
The EMAS group [16] recently reported 4.3 year follow-
up data on 2599 men aged 40–79 and concluded that men
with a baseline TT of 8 nmol/L or less and sexual symptoms
had a 3-fold increased mortality and a 5-fold increased risk
of cancer death.There authors concluded that there is a small
number of men with low testosterone at considerable risk of
early death.
A recent 10 year study from Western Australia involving
3690 men followed up from 2001–2010 concluded that TT
and FT levels in the normal range were associated with
decreased all-cause and cardiovascular mortality, for the
first time suggesting that both low and DHT are associated
with all-cause mortality and higher levels of DHT reduced
cardiovascular risk [17].
Six published studies usually involving small samples
have shown that low TT and FT are associated with CAD and
4 have shown no association [18]. Four studies have shown
inverse associations between low TT or FT (Table 2) and the
severity of CAD [18]. One involved 803 men assessed by
Gensini score, based on the location and number of stenotic
coronary artery segments and degree of luminal narrowing
[19]. Such studies do not establish whether low TT or FT is a
cause or a consequence of CAD.
3.1. Mortality Studies from High Risk Groups. Malkin et al.
[20] followed up 930 men referred with coronary artery
disease for 6.9 years. The prevalence of hypogonadism was
24%, mortality rates were 21% versus 12% (𝑃 = 0.002)
for hypogonadal men versus eugonadal, and the study was
halted early at 6.9 years. Only beta-blocker therapy and left
ventricular failure were found to have a greater influence on
survival.
Muraleedaran [21] et al. screened a primary care diabetic
population of 587 patients and followed them up for 5.8
years. They found that 475 of men had normal TT levels,
22% were overtly hypogonadal (<8 nmol/L), and 31% were
in the borderline range. These percentages were in close
agreement with earlier publications by Kapoor [22] et al. and
Hackett et al. [23]. The mortality rate [21] over 5 years in
the hypogonadal group was 17.2% versus 9% in the normal
testosterone cohort.The effect of treatmentwithTRT reduced
the mortality rate of treated cohort (8.4%) to that of the
eugonadal group whereas the mortality for the untreated
remained high at 19.2%, after adjustment for all confounding
factors.
3.2. Effect of Low Testosterone on Surrogate Markers for
Cardiovascular Risk. Decreases in serum total cholesterol
(TC) have been noted as early as after 4 weeks [23] but most
studies have reported a decrease after 3 months [24]. Greater
reductions were seen in obese men [24] with metabolic syn-
drome.TheMRFIT [25] study showed that hypogonadalmen
had slightly increased triglycerides and HDL, leading to the
suggestion that TRTmight be expected to lower triglycerides
and HDL. A recently published 5-year registry involving 230
men treated with long acting testosterone showed highly
significant reductions in TC, LDL, and triglycerides with
increase in HDL, associated with significant reduction in
weight, BMI, and visceral fat [26].
The decrease in serum triglycerides follows a similar
pattern: after 4 weeks with decrease over 9 months [25] and
maximum effect at 12 months [25]. The decrease in low-
density lipoprotein cholesterol seems somewhat slower: after
3 months, after 40–44 weeks, or after 12 months [25]
Studies have found both an increase and decrease in HDL
cholesterol [26–28] dependent on the presence of diabetes
or the use of statins. TRT has also been shown to reduce
fibrinogen to levels similar to fibrates. Low androgen levels
are associatedwith an increase in inflammatorymarkers [24].
A decline was noted in IL6 and TNF-alpha within 16 weeks
[27] and in another study after 16 weeks [24]. In the Moscow
study, C-reactive protein was reduced by TRT at 30 weeks
versus placebo [27].
Several of the above studies have shown reduction inwaist
circumference, visceral fat, and BMI [26–28]. Preliminary
longer term studies suggest that considerable weight loss
can be seen for up to 4 years. Placebo controlled studies in
untreated hypertension are difficult to conduct for ethical
reasons. In some studies, a decline in diastolic blood pressure
has been observed, after 3–9 months [24, 26] and in systolic
blood pressure [24, 26].Maximum effects were observed after
12 months and up to 5 years [24, 26].
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Table 2: Association between testosterone level and severity of coronary artery disease.
Study name Subfraction of testosteroneused for analysis
Method of measuring CAD
severity Main findings Remarks
Dobrzycki et al.
[34]
(CCS, 𝑛 = 96)
TT, FT, FAI Duke index∗ Inverse correlation betweenFT and CAD severity 𝑟 = −0.69, 𝑃 = 0.048
Rosano et al. [35]
(CCS, 𝑛 = 129) TT Coronary artery score
∗∗
Inverse correlation between
TT and CAD severity 𝑟 = −0.52, 𝑃 < 0.01
Li et al. [36]
(CCS, 𝑛 = 803) TT Genisi score
∗∗∗
Inverse correlation between
TT and CAD severity 𝑟 = −0.188, 𝑃 < 0.001
Phillips et al. [37]
(CCS, 𝑛 = 55) TT, FT
Visual estimation of coronary
artery occlusion and calculation
of mean percent occlusion∗∗∗∗
Inverse correlation between
TT and FT levels and CAD
severity
TT: 𝑟 = −0.43, 𝑃 < 0.02;
FT: 𝑟 = −0.62, 𝑃 < 0.001
CAD indicates coronary artery disease; CCS: case-control study; FAI: free androgen index; FT: free testosterone; TT: total testosterone.
∗Duke prognostic coronary artery index: a prognostic tool involving the extent and severity of atherosclerotic lesions in coronary arteries.
∗∗Coronary artery score: authors multiplied the degree of coronary artery obstruction by the number of stenoses.
∗∗∗Genisi score: calculated based on location and number of stenotic coronary artery segments, and degree of luminal narrowing.
∗∗∗∗Authors visually estimated the maximum percent reduction in luminal diameter of the left main, left anterior descending, left circumflex, and right
coronary arteries. The mean of these 4 values was used to estimate CAD severity.
3.3. Effects on Angina Threshold and Heart Failure. Men
with angiographically proven CAD (coronary artery disease)
have significantly lower testosterone levels [29] compared
to controls (𝑃 < 0.01) and there was a significant inverse
relationship between the degree of CAD and TT (total
testosterone) levels (𝑟 = −0.52, 𝑃 < 0.01). Nearly 25% of men
presenting for coronary angiography had testosterone levels
in the low hypogonadal range and some 50% had a TT of less
than 11 nmol/L [30].
Studies have shown pharmacological doses of testos-
terone to relax coronary arteries when injected intraluminally
[39] and to produce modest but consistent improvement in
exercise-induced angina and reverse associated ECG changes
[40]. The mechanism of action is via blockade of calcium
channels with effect of similar magnitude to nifedipine [40].
Inmen with chronic stable angina pectoris, the ischaemic
threshold increased after 4 weeks of TRT and a recent study
demonstrates improvement continuing beyond 12 months
[39, 40]. Exercise capacity in men with chronic heart failure
increased after 12 weeks [30], predominantly through the
improvement in skeletal muscle performance.
Lower levels of endogenous testosterone have been shown
to be associated with longer duration of the QTc interval
and TRT has been shown to reverse this effect [41]. Carotid
artery intimal thickness is associated with low endogenous
testosterone suggesting an increased risk of atherosclerosis
[31].
A trial of 209 elderly frail men [32] over 65 randomised to
receive either placebo or 100 g of topical testosterone gel was
terminated early as there were 23 cardiac events (2 deaths) in
the 106 men in the testosterone group versus 5 in the placebo
group, despite positive results in study end points. These
events included myocardial infarction and dysrhythmias and
hypertension. The authors conceded that there were more
cardiovascular comorbidities in the active treatment group
and that the starting dose and escalation were outside the
product licence. The active treatment group had more severe
CAD. The study involved rapid escalation up to 150mg per
day, above the manufacturers recommended dose and many
of the events were reported with inadequate validation.
3.4. Testosterone, Insulin Resistance, and Type 2 Diabetes.
Studies have shown an inverse relationship between serum
testosterone and fasting blood glucose and insulin levels
[33]. Both hyperinsulinaemia and low testosterone have
been shown to predict the development of type 2 diabetes
(T2D) [42, 43]. Medications such as chronic analgesics,
anticonvulsants, 5ARIs, and androgen ablation therapy are
associated with increased risk of testosterone deficiency and
insulin resistance [1, 2].
Hypogonadism is a common feature of the metabolic
syndrome [42, 43]. Intraabdominal adiposity (IAA) drives
the progression of multiple risk factors directly, through the
secretion of excess free fatty acids, inflammatory adipokines,
and decreased secretion of adiponectin [44]. The important
contributions of IAA to dyslipidaemia and insulin resistance
provide an indirect, though clinically important, link to the
genesis and progression of atherosclerosis and cardiovascular
disease [44]. The presence of excess IAA is an important
determinant of cardiometabolic risk. The INTERHEART
study [45] involving 29,972 participants examined the con-
tributory factors involved in first AMI (acute myocardial
infarction) and found IAA to be an important predictive
factor and recommended waist circumference or hip-waist
ratio as a standard measurement of cardiovascular risk.
Women with T2D or metabolic syndrome characteristically
have low SHBG and high free testosterone [6]. The precise
interaction between insulin resistance, visceral adiposity,
and hypogonadism is, as yet, unclear but the important
mechanisms are through increased aromatase production,
raised leptin levels, and increase in inflammatory kinins [46].
In obese males, levels of testosterone are reduced in
proportion to degree of obesity. The first step in reducing
visceral fat is diet and lifestyle change [46]. Patients should
be advised to switch to a low glycaemic diet, providing
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Table 3: Outcome of therapy with long acting TU in a population of men with type 2 diabetes and hypogonadism (BLAST) Hackett et al.
IJCP Dec 2013 [38].
HbA1c
(%)
>7.5
Weight
(kg)
BMI
(kg/m2)
WC
(cm)
TC
(mmol/L)
EF
(TT < 8 nmol/L)
AMS
(points) HADS-D
GEQ
(% imp)
30 weeks
−0.41 −0.7 −0.3 −2.5 −0.25 +3.0 −5.3 −1.01 46
𝑃 value 0.007 0.13 0.01 0.012 0.025 0.006 0.095 0.64 <0.001
82 weeks
−0.89 −2.7 −1.00 −4.2 −0.19
+4.31
+9.57
PDE5I
−8.1 −2.18 67–70
𝑃 value 0.009 0.016 0.019 <0.001 0.035 0.003 0.001 0.001 0.0001
carbohydrate that does not increase glucose levels that means
reducing potatoes and bread and substituting natural rice
and full corn. Men should be encouraged to combine aerobic
exercise with strength training. As muscle increases, glucose
will be burned more efficiently and insulin levels will fall. A
minimum of 30 minutes exercise three times weekly should
be advised [46].
Men with low testosterone levels show less diurnal vari-
ation compared with younger men with normal levels [1].
Testosterone increases levels of fast-twitchmuscle fibres [46].
By increasing testosterone, levels of type 2 fibres increase and
glucose burning improves. Weight loss will increase levels of
testosterone and augment the effects of lifestyle and exercise
advice [47].
Diabetes specialists have traditionally considered the
fall in testosterone level as being a consequence of obesity
but studies now clearly show that low testosterone leads
to visceral obesity and metabolic syndrome and is also a
consequence of obesity [4]. Large long-term studies have
shown that baseline levels of testosterone predict the later
development of type 2 diabetes [25, 42, 43]. In the case
of MMAS [43], a baseline total testosterone of less than
10.4 nmol/L was associated with a greater than 4-fold inci-
dence of type 2 diabetes over the next 9 years and NHANES-
III followed upmen from as young as 20 and found a similar 4
times greater prevalence independent of obesity or ethnicity
[42]. Diabetes UK data 2010 [48] showed the prevalence of
type 2 diabetes in men aged 35–44 to be doubled that of
women despite men in that age group having lower levels of
obesity and taking more exercise. This effect was even more
marked in southern Asian men [48]. A study has recently
commenced in Australia to establish whether treating young
obese men with low testosterone will reduce the incidence of
type 2 diabetes.
There is high level evidence that TRT improves insulin
resistance, as measured by HOMA-IR [49–52], and reduces
HbA1c [49] by approximately 0.7% by 18 months [53] and
inflammatory markers (CRP, IL6, and TNF-alpha) in men
with type 2 diabetes and metabolic syndrome [26–28]. There
is also high level of evidence for reduction in total cholesterol,
weight, BMI [26–28], and visceral fat (a significantmarker for
CV risk) and improvement of lean muscle mass. The BLAST
study [53, 54] suggested that men with depression (23% of
the cohort with diabetes) were markedly less responsive to
testosterone and that improvement in metabolic parameters
required sustained levels of testosterone above 12 nmol/L [53,
54] (Table 3).
A recent 5 year registry of 255 men age 36–69 [26]
treated with long acting TU has shown mean reductions in
waist circumference of 8.5 cm, weight reduction of 15.5 kg,
total cholesterol by 2.4mmol/L, reduction in HDL, and
triglycerides with HbA1c by 0.9% (7.06 to 6.16).
3.5. The Effects of Testosterone Replacement Therapy on Car-
diovascular Mortality. A prospective recent study of 587men
with type 2 diabetes [21] involved 5.8 years follow-up. Low
testosterone was defined as TT <10.4 nmol/L. Fifty-eightmen
were treated with testosterone for 2 years or more. The
mortality rate was 20% in the untreated group and 9.1% in the
normal group independent of comorbidities and therapies.
Mortality was 8.6% in the treated group (𝑃 = 0.049)
(Figure 1).
A similar retrospective US study involved 1031 men
with 372 on TRT. The cumulative mortality was 21% in the
untreated group versus 10% (𝑃 = 0.001) in the treated
group with the greatest effect in younger men and those with
type 2 diabetes [55]. In a recent paper of 145 patients with
first ischaemic stroke and diabetes, 66% were found to be
hypogonadal, and in the testosterone treated group 7% had
a recurrence of stroke in 2 years versus 16.6% in the control
group with 28% of the treated men returning to work versus
6%of the control group.Therewere significant improvements
in lipid profile and HbA1c [56].
A recent retrospective US study of 8709 men [57] with
baseline TT of 10.4 nmol undergoing coronary angiography
involved follow-up for mean 840 days. In the cohort of
7486 patients not receiving testosterone therapy, 681 died,
420 had MIs, and 486 had strokes. Among 1223 patients
receiving testosterone therapy, 67 died, 23 had MIs, and
33 had strokes. At first sight these results would closely
agree with the findings in [21, 55], but a complex statistical
analysis reversed the trend and concluded that there was a
greater risk in the TRT group. There were concerns that 1132
patients experiencing eventswere excluded because theywere
prescribed TRT after the event when surely these should have
been included in the untreated group, increasing the events by
70%.
The baseline TT was 1 nmol/L lower in the treated
group and previous studies show that this may increase the
mortality by up to 30%, yet this was not considered in the 50
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Figure 1: Low testosterone predicts increased mortality and testosterone therapy improves survival in 587 men with type 2 diabetes (mean
follow-up: 5.8 years) Muraleedaran et al. [21].
confounders for analysis. Symptoms were not considered, yet
these are key to the diagnosis of hypogonadism. Men were
likely to be treated with TRT on the basis of symptoms if they
suffered from erectile dysfunction, and the presence of ED
has been shown to be an independent risk factor, particularly
in hypogonadal men, increasing the risk of cardiac events by
over 50% [16, 58].
Therapies used were mainly short acting injection and
patches, both with high discontinuation rates. 16% filled only
one prescription but were included in the “treatment” group.
Only 60%had any record of a follow-up testosterone level and
in those themean treatment level was 10.2 nmol/L, suggesting
suboptimal therapy.
Despite these issues, the paper was given an editorial
and a separate paper warning patients about the risks of
testosterone was included in the same journal [59]. The level
of criticism of this paper led to an immediate revision of
the conclusions shortly after publication. A recent online
publication on ischaemic heart disease mortality in men
concluded optimal androgen levels are a biomarker for sur-
vival [17]. A recent systematic and meta-analysis of placebo-
controlled trials of T therapy lasting more than 12 weeks
concluded that testosterone therapy may increase the risk of
cardiovascular-related events [60] but most studies involved
small cohorts with a small number of events but once again
the nonrandomised studies failed to consider the impact of
symptoms as an indication for TRT prescribing.
A meta-analysis of 1000 patient years [61] versus placebo
suggests a slight reduction in myocardial infarction and CVA
but a reduction in coronary interventions. There was a 6%
incidence of raised haematocrit (>50%) without significant
consequences and no deaths in the active treatment group
versus 5 in the placebo cohort.
4. Long-Term Safety of Testosterone Therapy
on the Prostate
At least 7 observational studies have reported no association
of LUTS with serum testosterone level and 5 have shown an
inverse relationship [62]. No studies to date show an increase
in LUTS/BPH symptoms with higher serum testosterone
levels [62]. A recent long-term registry of 5 years TRT
shows sustained reduction in IPSS, postresidual volume, and
bladder wall thickness, despite minor increase in prostate
volume [63]. Another 5-year study involving a smaller cohort
showed no impact on LUTS/BPH parameters [64]. As TRT
has been shown to upregulate PDE5 [65] and enhance the
effect of PDE5Is (now an accepted therapy for both ED and
LUTS), it no longer seems logical to advice avoidance of TRT
in men with mild to moderate BPH.
Calof et al. [61] also found that patients on testosterone
were 12 times more likely to get a prostate biopsy but no
more likely to have a positive finding. Several meta-analyses
have failed to show a link between TRT and development
of prostate cancer [66] but some studies have shown a
tendency for more aggressive prostate cancer in men with
low testosterone.One recent study of 279 consecutive patients
referred for biopsy on the basis of abnormal DRE or raised
PSA found that low bioavailable testosterone and high SHBG
were associated with a 4.9- and 3.2-fold risk of positive biopsy
[67].
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Current EAU, ISSAM, and BSSM guidance [1, 2] is that
there is “no evidence TRT is associated with increased risk of
prostate cancer or activation of subclinical cancer.”
Despite these conclusions, many patients are deprived of
clinical andmetabolic benefit because of minor physiological
increases in PSA and concerns that no long-term study has
conclusively proved absolute safety.
5. Effects of Androgen Ablation Therapy
Menwith prostate cancer, treated with androgen deprivation,
develop an increase of fat mass with an altered lipid profile.
Total cholesterol by 9, 7, 11, and 26.5%, respectively. These
patients also appear to develop insulin resistance, hyperin-
sulinemia, and hyperglycaemia.The risks of diabetes mellitus
increase by 44% and mortality of cardiovascular diseases by
16% during a follow-up of up to 10 years [68]. The authors
concluded that before commencing ADT, the overall health,
comorbidities, and life expectancy of the patient need to be
fully assessed.
6. Testosterone and Erectile Dysfunction
Several studies have clearly shown that TRT can be effective as
monotherapy for ED [26, 28], in men without other multiple
comorbidities. A recent double blind placebo controlled
study in men with diabetes showed prompt improvement
in IIEF in men with severe hypogonadism and a secondary
improvement with 12 to 18 months of therapy, dependent
on obtaining prolonged sustained levels in the normal
range [69]. Results from a 5-year registry showed 12.3-point
improvements in IIEF in 260 men treated with long acting
TU [64]. A systematic review and meta-analysis of placebo-
controlled studies published in the past 30 years aimed to
study effects of testosterone on the different domains of sexual
life. This latter study concluded that T treatment might be
useful for improving vasculogenic ED in selected subjects
with low or low-normal T levels [70].
Erectile dysfunction is an established marker for future
cardiovascular risk and the major presenting symptom lead-
ing to a diagnosis of low testosterone [58]. Current guidelines
suggest that all patients presenting with ED, irrespective
of age, should be screened for low testosterone, as it is a
potentially curable cause of ED, especially in men without
othercomorbidities [1, 2]. NICE guidance [71] suggests that
all men with type 2 diabetes be assessed for ED annually
and the GP contract now includes routine assessment for
ED, and increased demand for testosterone supplementation
will be a natural consequence of this correction of previous
underdiagnosis and undertreatment [72].
7. Conclusions
Men with low testosterone usually present with bothersome
symptoms, particularly ED, and require treatment to address
those problems, not simply for cardiovascular prevention
purposes. The benefits of conventional cardiovascular risk
reduction with exercise and weight reduction are fundamen-
tal to management but are frequently unsuccessful. There
is a considerable body of evidence that low testosterone is
associated with increased cardiovascular and cancer mor-
tality. A policy of taking little or no action for these men
based on concerns of increased cardiovascular and cancer
risk associated with physiological replacement would seem
illogical. There is considerable evidence of modest cardiac
and metabolic benefits that are shown to reduce cardiovas-
cular risk plus sexual, mood, and quality of life changes
associated with restoring testosterone levels. These may add
up to substantial benefit to many patients. These benefits
may potentially denied to patients by fears over prostate
and cardiac risk that is not currently supported by evidence.
Ideally, we need large long-term studies to resolve these issues
with certainty but such studies are unlikely to be done for
logistic and financial reasons. Until then patients require
advice and treatment based on the current best evidence.
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